This is Dr. David
I don't know much about it
not much data out there for this new agent
Xilonix is the first antibody therapy to neutralize biological activity of interleukin-1 alpha (IL-1alpha), a potent anti-inflammatory signaling molecule known to promote the growth and spread of tumors
Among responders (in both treatment and placebo arms), clinical response was associated with a 2.7-fold increase in overall survival (11.5 versus 4.2 months in responders vs. non-responders, respectively). Overall survival was not compared between treatment arms because after 8 weeks, all patients were eligible to receive study drug.
let me know if you have questions.